Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INTS
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
INTS
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

INTS Similar Chart Price Prediction

The price of INTS is predicted to go up -34.22%, based on the high correlation periods with SNDL. The similarity of these two price pattern on the periods is 97.77%.

stocks logo

INTS

stocks logo

SNDL

Down: -34.22%Similarity: 97.77%

INTS Revenue Forecast

INTS EPS Forecast

INTS FAQs

What is bull’s view on INTS?

Intensity Therapeutics (INTS) has a bullish outlook with a price target of $8.50, as per Alliance Global Partners' January 2025 rating. The optimism stems from the potential of INT230-6, a Phase 3 drug targeting advanced cancers, valued at $8. The stock's current price of $2.27 offers significant upside potential.

What is bear's view on INTS?

The bear's view on INTS stock is negative due to weak fundamentals and recent dilution concerns. The stock is trading at $3.05, significantly below the $5-$8.50 price targets set by analysts, reflecting skepticism about its growth potential. Additionally, the Q2 2024 EPS miss (-$0.36 vs. -$0.32 expected) and lack of revenue highlight ongoing financial struggles.

INTS VS S&P500

Ask Intellectia about INTS

INTS Analyst's Forecast

James Molloy

Alliance Global Partners

Strong Buy

Price Target

$8.5

Upside

+274.45%

Alliance Global Partners initiated coverage of Intensity Therapeutics with a Buy rating and $8.50 price target. Intensity is developing INT230-6, a Phase 3 asset that both decreases the tumor burden while also activating an increased immune system response to better recognize and target the cancer, for advanced soft tissue sarcoma and triple negative breast cancer. The firm values INT230-6 for STS at $6 per share, INT230-6 for TNBC at $2 per share, and the remaining compounds and cash at 50c per share, the analyst noted.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free